CSF1 and neoplasm: Inflammatory monocyte mobilization decreases patient survival, and targeting the CCL2/CCR2 or CSF1/CSF1R axis that allows targeting macrophages or myeloid cell lineages improves chemotherapeutic efficacy and anti-tumour T-cell response [44,54,56].